Cell cycle in sporadic melanoma
Sporadic melanoma is a neoplasm whose etiology has not been fully investigated. Contemporary achievements in molecular biology have made it possible to localize the genes whose damage can contribute to the initiation of neoplastic transformation of melanocytes and lead to a progression of the diseas...
Saved in:
| Published in | International journal of dermatology Vol. 41; no. 9; pp. 550 - 556 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Science Ltd
01.09.2002
Blackwell Science Blackwell Publishing Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0011-9059 1365-4632 |
| DOI | 10.1046/j.1365-4362.2002.01601.x |
Cover
| Abstract | Sporadic melanoma is a neoplasm whose etiology has not been fully investigated. Contemporary achievements in molecular biology have made it possible to localize the genes whose damage can contribute to the initiation of neoplastic transformation of melanocytes and lead to a progression of the disease. The majority of these genes are responsible for the correct progression of phase G1 of the cell cycle. Phase G1 of the cell cycle is subject to control by many protooncogenes and antioncogenes, which constitute the pRb or p53 pathway, damage to which can lead to the development of malignant melanoma. The present paper discusses disorders in the control of phase G1 of the cell cycle in sporadic melanoma. |
|---|---|
| AbstractList | Sporadic melanoma is a neoplasm whose etiology has not been fully investigated. Contemporary achievements in molecular biology have made it possible to localize the genes whose damage can contribute to the initiation of neoplastic transformation of melanocytes and lead to a progression of the disease. The majority of these genes are responsible for the correct progression of phase G1 of the cell cycle. Phase G1 of the cell cycle is subject to control by many protooncogenes and antioncogenes, which constitute the pRb or p53 pathway, damage to which can lead to the development of malignant melanoma. The present paper discusses disorders in the control of phase G1 of the cell cycle in sporadic melanoma. Sporadic melanoma is a neoplasm whose etiology has not been fully investigated. Contemporary achievements in molecular biology have made it possible to localize the genes whose damage can contribute to the initiation of neoplastic transformation of melanocytes and lead to a progression of the disease. The majority of these genes are responsible for the correct progression of phase G1 of the cell cycle. Phase G1 of the cell cycle is subject to control by many protooncogenes and antioncogenes, which constitute the pRb or p53 pathway, damage to which can lead to the development of malignant melanoma. The present paper discusses disorders in the control of phase G1 of the cell cycle in sporadic melanoma.Sporadic melanoma is a neoplasm whose etiology has not been fully investigated. Contemporary achievements in molecular biology have made it possible to localize the genes whose damage can contribute to the initiation of neoplastic transformation of melanocytes and lead to a progression of the disease. The majority of these genes are responsible for the correct progression of phase G1 of the cell cycle. Phase G1 of the cell cycle is subject to control by many protooncogenes and antioncogenes, which constitute the pRb or p53 pathway, damage to which can lead to the development of malignant melanoma. The present paper discusses disorders in the control of phase G1 of the cell cycle in sporadic melanoma. |
| Author | Czajkowski, Rafał Krzyżyńska-Malinowska, Ewa Drewa, Tomasz Woźniak, Alina |
| Author_xml | – sequence: 1 givenname: Rafał surname: Czajkowski fullname: Czajkowski, Rafał email: rafal.czajkowski@pf.pl organization: From the Departments of Dermatology and – sequence: 2 givenname: Tomasz surname: Drewa fullname: Drewa, Tomasz organization: Biology, Ludwik Rydygier Medical University, Bydgoszcz, Poland – sequence: 3 givenname: Alina surname: Woźniak fullname: Woźniak, Alina organization: Biology, Ludwik Rydygier Medical University, Bydgoszcz, Poland – sequence: 4 givenname: Ewa surname: Krzyżyńska-Malinowska fullname: Krzyżyńska-Malinowska, Ewa organization: Biology, Ludwik Rydygier Medical University, Bydgoszcz, Poland |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13966804$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12358822$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1u1DAUhS3Uik4LrwAREuySXtuxkyyohAZaWg1lA0Vic-XYjuQhP4OdETNvj0OmReoGVrbl79xz7HNKjvqht4QkFDIKuTxfZ5RLkeZcsowBsAyoBJrtnpDFfCE5OyILAErTCkR1Qk5DWMcjZzR_Sk4o46IsGVuQl0vbtone69Ymrk_CZvDKOJ10tlX90Kln5LhRbbDPD-sZ-Xr54cvyY7r6fHW9fLdKdR6dU2u0amowujaKNlZaQ6tcVFIX0VHWRV5URtXApKpyDYaDhrq2QpiGClYxw8_Im3nuxg8_tzaM2LmgYzbV22EbsIjBGedlBF89AtfD1vcxGzLGylJIARF6cYC2dWcNbrzrlN_j_bsj8PoAqKBV23jVaxf-crySsoQ8chczp_0QgrcNajeq0Q396JVrkQJOheAap3_HqRCcCsE_heAuDigfDXjw-Lf07Sz95Vq7_28dXt-8n3ZRn856F0a7e9Ar_wNlwQuB326v8PJu9YndrW7xO_8NeJGuUA |
| CODEN | IJDEBB |
| CitedBy_id | crossref_primary_10_1097_CMR_0b013e32831993f3 crossref_primary_10_1111_j_1610_0387_2005_05024_x crossref_primary_10_1111_j_1365_4632_2011_05289_x crossref_primary_10_1158_0008_5472_CAN_05_1387 crossref_primary_10_1097_00042728_200402002_00010 crossref_primary_10_1038_sj_jid_5700324 crossref_primary_10_1111_j_1600_0749_2006_00315_x crossref_primary_10_1038_modpathol_3800324 crossref_primary_10_1111_j_1365_4632_2010_04675_x crossref_primary_10_1111_j_0303_6987_2004_00205_x crossref_primary_10_1111_j_1524_4725_2004_30088_x |
| Cites_doi | 10.1111/1523-1747.ep12381544 10.1038/35092584 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 10.1097/00000372-199904000-00002 10.1054/bjoc.2000.1513 10.1074/jbc.274.51.36031 10.1067/mjd.2000.104687 10.1006/excr.1999.4688 10.1046/j.1365-2133.2001.04070.x 10.1038/sj.onc.1202803 10.1101/gad.13.12.1501 10.1016/S0190-9622(99)70042-3 10.1016/S0167-5699(98)01373-5 10.1136/oem.57.1.65 10.1006/excr.1997.3776 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-# 10.1111/j.1600-0560.1998.tb01748.x 10.5858/2001-125-0208-CDEIDN 10.1046/j.1523-1747.1999.00812.x 10.1016/S0923-1811(01)00085-8 10.1038/sj.bjc.6690147 10.1046/j.1523-1747.1998.00211.x 10.1007/s000180050265 10.1038/35004020 10.1111/1523-1747.ep12323809 10.1046/j.1365-4362.1999.00746.x 10.1001/archderm.135.3.261 10.1136/jcp.54.3.229 10.1002/(SICI)1097-0215(19970904)72:5<780::AID-IJC13>3.0.CO;2-D 10.1054/bjps.1999.3232 10.1038/sj.bjc.6690143 10.1002/(SICI)1097-0215(19980220)79:1<91::AID-IJC17>3.0.CO;2-K 10.1111/j.1600-0560.1997.tb00790.x 10.1200/JCO.1998.16.2.670 10.1084/jem.191.6.1005 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N 10.1054/bjoc.2001.1771 10.1146/annurev.med.50.1.57 10.1016/S0167-4781(00)00272-4 10.1023/A:1006396104073 10.1634/theoncologist.5-6-510 10.1038/35092592 10.1006/rtph.2000.1410 10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P 10.1056/NEJM199904293401707 10.1097/00000372-199806000-00006 10.1097/00008390-199904000-00005 10.1067/mjd.2001.114576 |
| ContentType | Journal Article |
| Copyright | 2003 INIST-CNRS Copyright Blackwell Scientific Publications Ltd. Sep 2002 |
| Copyright_xml | – notice: 2003 INIST-CNRS – notice: Copyright Blackwell Scientific Publications Ltd. Sep 2002 |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U7 C1K H94 K9. NAPCQ 7X8 |
| DOI | 10.1046/j.1365-4362.2002.01601.x |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-4632 |
| EndPage | 556 |
| ExternalDocumentID | 226267181 12358822 13966804 10_1046_j_1365_4362_2002_01601_x IJD1601 ark_67375_WNG_FVLM2VLN_Z |
| Genre | miscellaneous Journal Article Review |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29J 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AAQQT AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION IQODW AEUQT AFPWT CGR CUY CVF ECM EIF ESX NPM WRC WUP 7T5 7U7 C1K H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c4601-edcafb0dcbda1fe6ed194596c73216b7479dab026a94c0d30c0bbe55df15292d3 |
| IEDL.DBID | DR2 |
| ISSN | 0011-9059 |
| IngestDate | Fri Jul 11 16:16:50 EDT 2025 Fri Jul 25 10:09:14 EDT 2025 Wed Feb 19 02:33:46 EST 2025 Mon Jul 21 09:16:20 EDT 2025 Thu Apr 24 22:58:24 EDT 2025 Tue Jul 01 01:25:33 EDT 2025 Wed Aug 20 07:26:32 EDT 2025 Tue Sep 09 05:32:21 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Human Skin disease Sporadic Check Malignant tumor Review Carcinogenesis G1 Phase Regulation(control) C-Onc gene Cell cycle Malignant melanoma Skin Molecular biology Protooncogene Tumor suppressor gene |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4601-edcafb0dcbda1fe6ed194596c73216b7479dab026a94c0d30c0bbe55df15292d3 |
| Notes | ArticleID:IJD1601 ark:/67375/WNG-FVLM2VLN-Z istex:BF2F439F921CA04F6D5A9FA49B0EECCCA4ECBDF1 ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 12358822 |
| PQID | 222885650 |
| PQPubID | 5776 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_72142338 proquest_journals_222885650 pubmed_primary_12358822 pascalfrancis_primary_13966804 crossref_citationtrail_10_1046_j_1365_4362_2002_01601_x crossref_primary_10_1046_j_1365_4362_2002_01601_x wiley_primary_10_1046_j_1365_4362_2002_01601_x_IJD1601 istex_primary_ark_67375_WNG_FVLM2VLN_Z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2002 |
| PublicationDateYYYYMMDD | 2002-09-01 |
| PublicationDate_xml | – month: 09 year: 2002 text: September 2002 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England – name: Hoboken |
| PublicationTitle | International journal of dermatology |
| PublicationTitleAlternate | Int J Dermatol |
| PublicationYear | 2002 |
| Publisher | Blackwell Science Ltd Blackwell Science Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell Science – name: Blackwell Publishing Ltd |
| References | Kumar R, Smeds J, Lundh-Rozell B, et al. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 1999; 9: 138-147. Gelsleichter L, Gown AM, Zarbo RJ, et al. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2 and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995; 8: 530-535. Palmieri G, Cossu A, Ascierto PA, et al. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. Br J Cancer 2000; 83: 1707-1714. Karjalainen JM, Eskelinen MJ, Kellokoski JK, et al. p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 1999; 79: 895-902. Zerp SF, Van-Elsas A, Peltenburg LT, et al. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br J Cancer 1999; 79: 921-926. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16 (INK4a) with retention of p19 (ARF) predisposes mice to tumorigenesis. Nature 2001; 413: 86-91. Wong O, Raabe GK. A critical review of cancer epidemiology in the petroleum industry, with a meta-analysis of a combined database of more than 350,000 workers. Regul Toxicol Pharmacol 2000; 32: 78-98. Miracco C, Lavergne D, Nyongo A, et al. Malignant melanomas: search for human papillomaviruses. Arch Dermatol 2001; 137: 826-827. Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 1997; 24: 265-271. Pfahlberg A, Kolmel KF, Gefeller O. Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced melanoma. Br J Dermatol 2001; 144: 471-475. Gonzalgo ML, Bender CM, You EH, et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997; 57: 5336-5347. Haddad MM, Xu W, Schwahn DJ, et al. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16 (INK4) and p27 (KIP1) to CDKs, loss of E2F-binding activity and premature senescence of human melanocytes. Exp Cell Res 1999; 253: 561-572. Morgan MB, Cowper SE. Expression of p27 (kip1) in nevi and melanomas. Am J Dermatopathol 1999; 21: 121-124. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126. Peris K, Keller G, Chimenti S, et al. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol 1995; 105: 625-628. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A (p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42: 705-722. Fujimoto A, Morita R, Hatta N, et al. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 1999; 18: 2527-2532. Chana JS, Grover R, Wilson GD, et al. An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. Br J Plast Surg 2000; 53: 46-50. Saida T. Recent advances in melanoma research. J Dermatol Sci 2001; 26: 1-13. Israels ED, Israels LG. The cell cycle. Oncologist 2000; 5: 510-513. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001; 54: 229-235. Negrier S, Fervers B, Bailly C, et al. Cutaneous melanoma. Br J Cancer 2001; 84 (Suppl. 2): 81-85. Ewanowich C, Brynes RK, Medeiros LJ, et al. Cyclin D1 expression in dysplastic nevi. Arch Pathol Lab Med 2001; 125: 208-210. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237: 1-6. Langard S, Rosenberg J, Andersen A, et al. Incidence of cancer among workers exposed to vinyl chloride in polyvinyl chloride manufacture. Occup Environ Med 2000; 57: 65-68. Ruiz A, Pujana MA, Estivill X. Isolation and characterization of a novel human gene (C9orf11) on chromosome 9p21, a region frequently deleted in human cancer. Biochim Biophys Acta 2000; 1517: 128-134. Sauroja I, Smeds J, Vlaykova T, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000; 28: 404-414. Lubbe J, Reichel M, Burg G, et al. Absence of p53 mutations in cutaneous melanoma. J Invest Dermatol 1994; 102: 819-821. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6: 1845-1853. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512. Burden AD, Newell J, Andrew N, et al. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 1999; 135: 261-265. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340: 1341-1348. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999; 50: 57-74. Florenes VA, Faye RS, Maelandsmo GM, et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000; 6: 3614-3620. Smith KJ, Skelton M. Immune and gene therapy for melanoma, and the immunobiology of melanoma. Int J Dermatol 1999; 38: 490-508. Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today 1999; 20: 5-7. Kumar R, Sauroja I, Punnonen K, et al. Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 1998; 23: 273-277. Oren M, Rotter V. Introduction: p53 - the first twenty years. Cell Mol Life Sci 1999; 55: 9-11. Bartek J, Lukas J, Bartkova J. Perspective: defects in cell cycle control and cancer. J Pathol 1999; 187: 95-99. Bales ES, Dietrich C, Bandyopadhyay D, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113: 1039-1046. Halaban R. Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev 1999; 18: 333-343. Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol 1999; 41: 143-164. Guldberg P, Kirkin AF, Gronbaek K, et al. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 1997; 72: 780-783. Funk JO, Schiller PI, Barrett MT, et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291-296. Carnero A, Hudson JD, Price CM, et al. p16 (INK4A) and p19 (ARF) act in overlapping pathways in cellular immortalization. Nature Cell Biol 2000; 2: 148-155. Krimpenfort P, Quon KC, Moll WJ, et al. Loss of p16 (INK4a) confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83-86. Halaban R, Cheng E, Smicun Y, et al. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000; 191: 1005-1015. Akslen LA, Monstad SE, Larsen B, et al. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998; 79: 91-95. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761. Sparrow LE, Eldon MJ, English DR, et al. p16 and p21 WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255-261. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16: 670-682. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 36031-36034. Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998; 110: 932-938. 2001; 144 1997; 237 2000; 28 2000; 6 2000; 5 1997; 24 2000; 42 1999; 340 1999; 187 1999; 21 2000; 2 1999; 20 2001; 26 1999; 41 2000; 1517 2001; 44 1998; 110 1998; 20 2001; 84 1998; 23 2001; 125 1998; 25 2000; 191 1995; 8 1999; 9 1998; 16 1994; 102 1997; 72 2000; 57 1999; 18 2000; 32 1999; 38 1997; 57 2000; 53 1999; 13 1999; 274 2000; 83 1999; 79 1999; 253 1999; 55 1995; 105 1999; 135 1999; 113 1999; 50 2001; 137 2001; 413 2001; 54 1998; 79 e_1_2_5_27_2 e_1_2_5_48_2 e_1_2_5_46_2 e_1_2_5_23_2 e_1_2_5_44_2 Florenes VA (e_1_2_5_43_2) 2000; 6 e_1_2_5_21_2 e_1_2_5_42_2 e_1_2_5_13_2 e_1_2_5_38_2 e_1_2_5_9_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_34_2 e_1_2_5_5_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_53_2 e_1_2_5_3_2 e_1_2_5_17_2 e_1_2_5_19_2 Gonzalgo ML (e_1_2_5_25_2) 1997; 57 e_1_2_5_30_2 e_1_2_5_51_2 Straume O (e_1_2_5_29_2) 2000; 6 e_1_2_5_26_2 e_1_2_5_49_2 e_1_2_5_24_2 e_1_2_5_47_2 Miracco C (e_1_2_5_7_2) 2001; 137 e_1_2_5_22_2 e_1_2_5_45_2 e_1_2_5_20_2 e_1_2_5_28_2 e_1_2_5_41_2 e_1_2_5_14_2 e_1_2_5_37_2 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_8_2 e_1_2_5_10_2 e_1_2_5_33_2 e_1_2_5_6_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_54_2 e_1_2_5_4_2 e_1_2_5_2_2 e_1_2_5_18_2 Gelsleichter L (e_1_2_5_50_2) 1995; 8 e_1_2_5_39_2 Ewanowich C (e_1_2_5_40_2) 2001; 125 e_1_2_5_52_2 |
| References_xml | – reference: Israels ED, Israels LG. The cell cycle. Oncologist 2000; 5: 510-513. – reference: Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998; 110: 932-938. – reference: Akslen LA, Monstad SE, Larsen B, et al. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998; 79: 91-95. – reference: Bartek J, Lukas J, Bartkova J. Perspective: defects in cell cycle control and cancer. J Pathol 1999; 187: 95-99. – reference: Kumar R, Sauroja I, Punnonen K, et al. Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 1998; 23: 273-277. – reference: Fujimoto A, Morita R, Hatta N, et al. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 1999; 18: 2527-2532. – reference: Gelsleichter L, Gown AM, Zarbo RJ, et al. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2 and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995; 8: 530-535. – reference: Langard S, Rosenberg J, Andersen A, et al. Incidence of cancer among workers exposed to vinyl chloride in polyvinyl chloride manufacture. Occup Environ Med 2000; 57: 65-68. – reference: Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16: 670-682. – reference: Guldberg P, Kirkin AF, Gronbaek K, et al. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 1997; 72: 780-783. – reference: Ruiz A, Pujana MA, Estivill X. Isolation and characterization of a novel human gene (C9orf11) on chromosome 9p21, a region frequently deleted in human cancer. Biochim Biophys Acta 2000; 1517: 128-134. – reference: Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 36031-36034. – reference: Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761. – reference: Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16 (INK4a) with retention of p19 (ARF) predisposes mice to tumorigenesis. Nature 2001; 413: 86-91. – reference: Lubbe J, Reichel M, Burg G, et al. Absence of p53 mutations in cutaneous melanoma. J Invest Dermatol 1994; 102: 819-821. – reference: Chana JS, Grover R, Wilson GD, et al. An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. Br J Plast Surg 2000; 53: 46-50. – reference: Krimpenfort P, Quon KC, Moll WJ, et al. Loss of p16 (INK4a) confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83-86. – reference: Karjalainen JM, Eskelinen MJ, Kellokoski JK, et al. p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 1999; 79: 895-902. – reference: Funk JO, Schiller PI, Barrett MT, et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291-296. – reference: Morgan MB, Cowper SE. Expression of p27 (kip1) in nevi and melanomas. Am J Dermatopathol 1999; 21: 121-124. – reference: Burden AD, Newell J, Andrew N, et al. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 1999; 135: 261-265. – reference: Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340: 1341-1348. – reference: Carnero A, Hudson JD, Price CM, et al. p16 (INK4A) and p19 (ARF) act in overlapping pathways in cellular immortalization. Nature Cell Biol 2000; 2: 148-155. – reference: Negrier S, Fervers B, Bailly C, et al. Cutaneous melanoma. Br J Cancer 2001; 84 (Suppl. 2): 81-85. – reference: Florenes VA, Faye RS, Maelandsmo GM, et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000; 6: 3614-3620. – reference: Gonzalgo ML, Bender CM, You EH, et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997; 57: 5336-5347. – reference: Oren M, Rotter V. Introduction: p53 - the first twenty years. Cell Mol Life Sci 1999; 55: 9-11. – reference: Wong O, Raabe GK. A critical review of cancer epidemiology in the petroleum industry, with a meta-analysis of a combined database of more than 350,000 workers. Regul Toxicol Pharmacol 2000; 32: 78-98. – reference: Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today 1999; 20: 5-7. – reference: Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126. – reference: Peris K, Keller G, Chimenti S, et al. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol 1995; 105: 625-628. – reference: Kumar R, Smeds J, Lundh-Rozell B, et al. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 1999; 9: 138-147. – reference: Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237: 1-6. – reference: Ewanowich C, Brynes RK, Medeiros LJ, et al. Cyclin D1 expression in dysplastic nevi. Arch Pathol Lab Med 2001; 125: 208-210. – reference: Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A (p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42: 705-722. – reference: Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol 1999; 41: 143-164. – reference: Halaban R, Cheng E, Smicun Y, et al. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000; 191: 1005-1015. – reference: Smith KJ, Skelton M. Immune and gene therapy for melanoma, and the immunobiology of melanoma. Int J Dermatol 1999; 38: 490-508. – reference: Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001; 54: 229-235. – reference: Haddad MM, Xu W, Schwahn DJ, et al. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16 (INK4) and p27 (KIP1) to CDKs, loss of E2F-binding activity and premature senescence of human melanocytes. Exp Cell Res 1999; 253: 561-572. – reference: Bales ES, Dietrich C, Bandyopadhyay D, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113: 1039-1046. – reference: Sauroja I, Smeds J, Vlaykova T, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000; 28: 404-414. – reference: Pfahlberg A, Kolmel KF, Gefeller O. Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced melanoma. Br J Dermatol 2001; 144: 471-475. – reference: Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 1997; 24: 265-271. – reference: Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512. – reference: Saida T. Recent advances in melanoma research. J Dermatol Sci 2001; 26: 1-13. – reference: Sparrow LE, Eldon MJ, English DR, et al. p16 and p21 WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255-261. – reference: Palmieri G, Cossu A, Ascierto PA, et al. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. Br J Cancer 2000; 83: 1707-1714. – reference: Halaban R. Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev 1999; 18: 333-343. – reference: Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999; 50: 57-74. – reference: Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6: 1845-1853. – reference: Zerp SF, Van-Elsas A, Peltenburg LT, et al. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br J Cancer 1999; 79: 921-926. – reference: Miracco C, Lavergne D, Nyongo A, et al. Malignant melanomas: search for human papillomaviruses. Arch Dermatol 2001; 137: 826-827. – volume: 79 start-page: 921 year: 1999 end-page: 926 article-title: p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis publication-title: Br J Cancer – volume: 125 start-page: 208 year: 2001 end-page: 210 article-title: Cyclin D1 expression in dysplastic nevi publication-title: Arch Pathol Lab Med – volume: 42 start-page: 705 year: 2000 end-page: 722 article-title: Melanoma genetics: an update with focus on the CDKN2A (p16)/ARF tumor suppressors publication-title: J Am Acad Dermatol – volume: 24 start-page: 265 year: 1997 end-page: 271 article-title: Overexpression of the cyclin‐dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma publication-title: J Cutan Pathol – volume: 18 start-page: 2527 year: 1999 end-page: 2532 article-title: p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma publication-title: Oncogene – volume: 1517 start-page: 128 year: 2000 end-page: 134 article-title: Isolation and characterization of a novel human gene (C9orf11) on chromosome 9p21, a region frequently deleted in human cancer publication-title: Biochim Biophys Acta – volume: 16 start-page: 670 year: 1998 end-page: 682 article-title: Molecular genetics of familial cutaneous melanoma publication-title: J Clin Oncol – volume: 144 start-page: 471 year: 2001 end-page: 475 article-title: Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation‐induced melanoma publication-title: Br J Dermatol – volume: 53 start-page: 46 year: 2000 end-page: 50 article-title: An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma publication-title: Br J Plast Surg – volume: 9 start-page: 138 year: 1999 end-page: 147 article-title: Loss of heterozygosity at chromosome 9p21 (INK4‐p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas publication-title: Melanoma Res – volume: 105 start-page: 625 year: 1995 end-page: 628 article-title: Microsatellite instability and loss of heterozygosity in melanoma publication-title: J Invest Dermatol – volume: 83 start-page: 1707 year: 2000 end-page: 1714 article-title: Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases publication-title: Br J Cancer – volume: 6 start-page: 3614 year: 2000 end-page: 3620 article-title: Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma publication-title: Clin Cancer Res – volume: 84 start-page: 81 issue: Suppl. 2 year: 2001 end-page: 85 article-title: Cutaneous melanoma publication-title: Br J Cancer – volume: 54 start-page: 229 year: 2001 end-page: 235 article-title: Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions publication-title: J Clin Pathol – volume: 137 start-page: 826 year: 2001 end-page: 827 article-title: Malignant melanomas: search for human papillomaviruses publication-title: Arch Dermatol – volume: 57 start-page: 5336 year: 1997 end-page: 5347 article-title: Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors publication-title: Cancer Res – volume: 79 start-page: 895 year: 1999 end-page: 902 article-title: p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival publication-title: Br J Cancer – volume: 55 start-page: 9 year: 1999 end-page: 11 article-title: Introduction: p53 – the first twenty years publication-title: Cell Mol Life Sci – volume: 38 start-page: 490 year: 1999 end-page: 508 article-title: Immune and gene therapy for melanoma, and the immunobiology of melanoma publication-title: Int J Dermatol – volume: 41 start-page: 143 year: 1999 end-page: 164 article-title: Loss of heterozygosity in human skin publication-title: J Am Acad Dermatol – volume: 20 start-page: 5 year: 1999 end-page: 7 article-title: New perspectives on immunobiology and immunotherapy of melanoma publication-title: Immunol Today – volume: 6 start-page: 1845 year: 2000 end-page: 1853 article-title: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki‐67) and poor prognosis in patients with vertical growth phase melanoma publication-title: Clin Cancer Res – volume: 72 start-page: 780 year: 1997 end-page: 783 article-title: Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma publication-title: Int J Cancer – volume: 57 start-page: 65 year: 2000 end-page: 68 article-title: Incidence of cancer among workers exposed to vinyl chloride in polyvinyl chloride manufacture publication-title: Occup Environ Med – volume: 21 start-page: 121 year: 1999 end-page: 124 article-title: Expression of p27 (kip1) in nevi and melanomas publication-title: Am J Dermatopathol – volume: 102 start-page: 819 year: 1994 end-page: 821 article-title: Absence of p53 mutations in cutaneous melanoma publication-title: J Invest Dermatol – volume: 25 start-page: 291 year: 1998 end-page: 296 article-title: p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma publication-title: J Cutan Pathol – volume: 413 start-page: 83 year: 2001 end-page: 86 article-title: Loss of p16 (INK4a) confers susceptibility to metastatic melanoma in mice publication-title: Nature – volume: 23 start-page: 273 year: 1998 end-page: 277 article-title: Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines publication-title: Genes Chromosomes Cancer – volume: 274 start-page: 36031 year: 1999 end-page: 36034 article-title: Regulation of the p53 tumor suppressor protein publication-title: J Biol Chem – volume: 253 start-page: 561 year: 1999 end-page: 572 article-title: Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16 (INK4) and p27 (KIP1) to CDKs, loss of E2F‐binding activity and premature senescence of human melanocytes publication-title: Exp Cell Res – volume: 110 start-page: 932 year: 1998 end-page: 938 article-title: Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions publication-title: J Invest Dermatol – volume: 44 start-page: 755 year: 2001 end-page: 761 article-title: The risk of melanoma in association with long‐term exposure to PUVA publication-title: J Am Acad Dermatol – volume: 50 start-page: 57 year: 1999 end-page: 74 article-title: The ubiquitin‐proteasome pathway and pathogenesis of human diseases publication-title: Annu Rev Med – volume: 187 start-page: 112 year: 1999 end-page: 126 article-title: The p53 pathway publication-title: J Pathol – volume: 135 start-page: 261 year: 1999 end-page: 265 article-title: Genetic and environmental influences in the development of multiple primary melanoma publication-title: Arch Dermatol – volume: 28 start-page: 404 year: 2000 end-page: 414 article-title: Analysis of G(1)/S checkpoint regulators in metastatic melanoma publication-title: Genes Chromosomes Cancer – volume: 32 start-page: 78 year: 2000 end-page: 98 article-title: A critical review of cancer epidemiology in the petroleum industry, with a meta‐analysis of a combined database of more than 350,000 workers publication-title: Regul Toxicol Pharmacol – volume: 18 start-page: 333 year: 1999 end-page: 343 article-title: Melanoma cell autonomous growth: the Rb/E2F pathway publication-title: Cancer Metastasis Rev – volume: 2 start-page: 148 year: 2000 end-page: 155 article-title: p16 (INK4A) and p19 (ARF) act in overlapping pathways in cellular immortalization publication-title: Nature Cell Biol – volume: 26 start-page: 1 year: 2001 end-page: 13 article-title: Recent advances in melanoma research publication-title: J Dermatol Sci – volume: 13 start-page: 1501 year: 1999 end-page: 1512 article-title: CDK inhibitors: positive and negative regulators of G1‐phase progression publication-title: Genes Dev – volume: 340 start-page: 1341 year: 1999 end-page: 1348 article-title: The pathogenesis of melanoma induced by ultraviolet radiation publication-title: N Engl J Med – volume: 5 start-page: 510 year: 2000 end-page: 513 article-title: The cell cycle publication-title: Oncologist – volume: 20 start-page: 255 year: 1998 end-page: 261 article-title: p16 and p21 WAF1 protein expression in melanocytic tumors by immunohistochemistry publication-title: Am J Dermatopathol – volume: 413 start-page: 86 year: 2001 end-page: 91 article-title: Loss of p16 (INK4a) with retention of p19 (ARF) predisposes mice to tumorigenesis publication-title: Nature – volume: 113 start-page: 1039 year: 1999 end-page: 1046 article-title: High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas publication-title: J Invest Dermatol – volume: 79 start-page: 91 year: 1998 end-page: 95 article-title: Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type publication-title: Int J Cancer – volume: 191 start-page: 1005 year: 2000 end-page: 1015 article-title: Deregulated E2F transcriptional activity in autonomously growing melanoma cells publication-title: J Exp Med – volume: 187 start-page: 95 year: 1999 end-page: 99 article-title: Perspective: defects in cell cycle control and cancer publication-title: J Pathol – volume: 237 start-page: 1 year: 1997 end-page: 6 article-title: The retinoblastoma protein pathway in cell cycle control and cancer publication-title: Exp Cell Res – volume: 8 start-page: 530 year: 1995 end-page: 535 article-title: p53 and mdm‐2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm‐2 and markers of cell proliferation in primary versus metastatic tumors publication-title: Mod Pathol – ident: e_1_2_5_46_2 doi: 10.1111/1523-1747.ep12381544 – volume: 8 start-page: 530 year: 1995 ident: e_1_2_5_50_2 article-title: p53 and mdm‐2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm‐2 and markers of cell proliferation in primary versus metastatic tumors publication-title: Mod Pathol – ident: e_1_2_5_32_2 doi: 10.1038/35092584 – ident: e_1_2_5_14_2 doi: 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 – ident: e_1_2_5_39_2 doi: 10.1097/00000372-199904000-00002 – ident: e_1_2_5_17_2 doi: 10.1054/bjoc.2000.1513 – ident: e_1_2_5_15_2 doi: 10.1074/jbc.274.51.36031 – ident: e_1_2_5_8_2 doi: 10.1067/mjd.2000.104687 – volume: 137 start-page: 826 year: 2001 ident: e_1_2_5_7_2 article-title: Malignant melanomas: search for human papillomaviruses publication-title: Arch Dermatol – ident: e_1_2_5_38_2 doi: 10.1006/excr.1999.4688 – ident: e_1_2_5_19_2 doi: 10.1046/j.1365-2133.2001.04070.x – ident: e_1_2_5_21_2 doi: 10.1038/sj.onc.1202803 – ident: e_1_2_5_12_2 doi: 10.1101/gad.13.12.1501 – ident: e_1_2_5_24_2 doi: 10.1016/S0190-9622(99)70042-3 – ident: e_1_2_5_53_2 doi: 10.1016/S0167-5699(98)01373-5 – ident: e_1_2_5_5_2 doi: 10.1136/oem.57.1.65 – ident: e_1_2_5_11_2 doi: 10.1006/excr.1997.3776 – ident: e_1_2_5_9_2 doi: 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-# – ident: e_1_2_5_23_2 doi: 10.1111/j.1600-0560.1998.tb01748.x – volume: 125 start-page: 208 year: 2001 ident: e_1_2_5_40_2 article-title: Cyclin D1 expression in dysplastic nevi publication-title: Arch Pathol Lab Med doi: 10.5858/2001-125-0208-CDEIDN – ident: e_1_2_5_37_2 doi: 10.1046/j.1523-1747.1999.00812.x – ident: e_1_2_5_54_2 doi: 10.1016/S0923-1811(01)00085-8 – ident: e_1_2_5_49_2 doi: 10.1038/sj.bjc.6690147 – ident: e_1_2_5_28_2 doi: 10.1046/j.1523-1747.1998.00211.x – ident: e_1_2_5_13_2 doi: 10.1007/s000180050265 – ident: e_1_2_5_31_2 doi: 10.1038/35004020 – ident: e_1_2_5_22_2 doi: 10.1111/1523-1747.ep12323809 – ident: e_1_2_5_51_2 doi: 10.1046/j.1365-4362.1999.00746.x – ident: e_1_2_5_18_2 doi: 10.1001/archderm.135.3.261 – ident: e_1_2_5_42_2 doi: 10.1136/jcp.54.3.229 – ident: e_1_2_5_44_2 doi: 10.1002/(SICI)1097-0215(19970904)72:5<780::AID-IJC13>3.0.CO;2-D – volume: 6 start-page: 1845 year: 2000 ident: e_1_2_5_29_2 article-title: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki‐67) and poor prognosis in patients with vertical growth phase melanoma publication-title: Clin Cancer Res – ident: e_1_2_5_27_2 doi: 10.1054/bjps.1999.3232 – ident: e_1_2_5_34_2 doi: 10.1038/sj.bjc.6690143 – ident: e_1_2_5_48_2 doi: 10.1002/(SICI)1097-0215(19980220)79:1<91::AID-IJC17>3.0.CO;2-K – ident: e_1_2_5_36_2 doi: 10.1111/j.1600-0560.1997.tb00790.x – ident: e_1_2_5_20_2 doi: 10.1200/JCO.1998.16.2.670 – ident: e_1_2_5_45_2 doi: 10.1084/jem.191.6.1005 – ident: e_1_2_5_30_2 doi: 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N – ident: e_1_2_5_2_2 doi: 10.1054/bjoc.2001.1771 – ident: e_1_2_5_16_2 doi: 10.1146/annurev.med.50.1.57 – ident: e_1_2_5_52_2 doi: 10.1016/S0167-4781(00)00272-4 – ident: e_1_2_5_41_2 doi: 10.1023/A:1006396104073 – ident: e_1_2_5_10_2 doi: 10.1634/theoncologist.5-6-510 – ident: e_1_2_5_33_2 doi: 10.1038/35092592 – volume: 6 start-page: 3614 year: 2000 ident: e_1_2_5_43_2 article-title: Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma publication-title: Clin Cancer Res – ident: e_1_2_5_6_2 doi: 10.1006/rtph.2000.1410 – ident: e_1_2_5_47_2 doi: 10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P – ident: e_1_2_5_3_2 doi: 10.1056/NEJM199904293401707 – ident: e_1_2_5_35_2 doi: 10.1097/00000372-199806000-00006 – volume: 57 start-page: 5336 year: 1997 ident: e_1_2_5_25_2 article-title: Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors publication-title: Cancer Res – ident: e_1_2_5_26_2 doi: 10.1097/00008390-199904000-00005 – ident: e_1_2_5_4_2 doi: 10.1067/mjd.2001.114576 |
| SSID | ssj0013214 |
| Score | 1.6938297 |
| SecondaryResourceType | review_article |
| Snippet | Sporadic melanoma is a neoplasm whose etiology has not been fully investigated. Contemporary achievements in molecular biology have made it possible to... |
| SourceID | proquest pubmed pascalfrancis crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 550 |
| SubjectTerms | Biological and medical sciences Cell Cycle - genetics Cell Cycle - physiology Dermatology G1 Phase - genetics G1 Phase - physiology Genes, cdc - physiology Humans Medical sciences Melanoma - genetics Melanoma - physiopathology Skin Neoplasms - genetics Skin Neoplasms - physiopathology Tumors of the skin and soft tissue. Premalignant lesions |
| Title | Cell cycle in sporadic melanoma |
| URI | https://api.istex.fr/ark:/67375/WNG-FVLM2VLN-Z/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-4362.2002.01601.x https://www.ncbi.nlm.nih.gov/pubmed/12358822 https://www.proquest.com/docview/222885650 https://www.proquest.com/docview/72142338 |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dT9swED8hJqG9MGCMhW6Qh4m3VEnjOMkjKisMQR8QX9qL5a9IU9t0oq0E_PXcOW6hEw9o4i2SZUdn39m_8_18B_BDpRydBltEuDlWESt1GqHbXERM8hzRQkZHOLEt-vzkip3eZree_0RvYZr8EIsLN7IMt1-TgUvVVCGJXXZbz9Bi-BPHNGhTrrSkTXgSGyiN_tFF50VAoUnzTTeCJUIKT-rxAc5XB1o6qT7QpN8Tc1JOcPKqpurFa7B0GeW6Y6r3CQZzARt2yqA9m6q2fvwn9-P7zMAGrHs0Gx426rcJK7begrVzH6__DPtdOxyG-gEbwz91SC60xLZwZIeyHo_kNlz1fl52TyJfkiHSDMeOrNGyUrHRysikstyapGRZyTUubMIV-ialkQr9OlkyHZs01rFSNstMhTih7Jj0C6zW49p-hZCnVWIzdG9yLhFVWInIqshKxlmVa65MAPl8-oX2-cqpbMZQuLg5ozdmJL8g-amaZkc4-cV9AMmi598mZ8cb-hy4FV50kHcD4rzlmbjpH4ve9dl55_qsL34HsLekAs9_SNFzLGIWQGuuE8LvBxNB92wFYuc4gP1FKxoyRWdkbcezicgp-R2aSQA7jSI9j0zPmRHIBcCdOrxZKPHr9Ii-dv-3Yws-uuo3jlP3DVandzP7HUHYVO0583oC4vscHA |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9tAEB5VINFeaOkDXArxoerNqR2v1_YR0aaBJjlUQFEvq31ZQhgHkUSi_fXMrDeBVBxQ1Zul1aw1uzO73zx2BuCjSjkaDbaI8HCsIlbqNEKzuYiY5DmihYyucMq2GPPBKTs-z859OyB6C9PWh1g63Egz3HlNCk4O6c8-LNlqOaVoMfyLSzXoUrG0pIuAct2F6wgh_eg9CCm0hb7JJ1giqPBpPT7E-ehMK3fVOi37LeVOyikuX9X2vXgMmK7iXHdR9V9CvWCxzU-57M5nqqv__FX98T-twSvY9IA2PGglcAue2eY1bIx8yP4NdA5tXYf6Nw6GF01IVrTEsfDK1rKZXMm3cNr_enI4iHxXhkgznDuyRstKxUYrI5PKcmuSkmUl17i3CVdonpRGKjTtZMl0bNJYx0rZLDMVQoWyZ9J3sNZMGrsDIU-rxGZo4eRcIrCwEsFVkZW4e1WuuTIB5Iv1F9qXLKfOGbVwoXNGz8yIf0H8U0PNnnD8i9sAkiXldVu24wk0n9wWLwnkzSWlveWZ-Dn-Jvpnw1HvbDgWvwLYX5GB-z-kaDwWMQtgdyEUwh8JU0GutgLhcxxAZzmKukwBGtnYyXwqcqp_h5oSwHYrSfcz04tmxHIBcCcPT2ZKHB1_oa_3_0rYgeeDk9FQDI_G33fhhWuG41LsPsDa7GZu9xCTzdS-07U7w3sgOg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9tAEB5VICEubWmhuDziQ9Wbgx2v1_axAsKjIaoqXuKy2pelKsFBJJFof31n1ptAKg4I9WZptbZmPLP7zc63MwBfVMoxaLBFhItjFbFSpxGGzUXEJM8RLWS0hRPbos-PL9jpdXbt-U90F6apDzE_cCPPcOs1OfidqfZ8VrJxcmJoMfyIYxq0qVZa0kY8ucw47poEkH52nmQUmjrfdCRYIqbwrB6f4Xz2TQtb1TJp_YGok3KM2quathfP4dJFmOv2qe47GMwkbOgpg_Z0otr6zz_FH_-PCt7DWw9nw2-N_a3BG1t_gJUzn7D_CK19OxyG-jcOhr_qkGJoiWPhrR3KenQr1-Gie3i-fxz5ngyRRq0mkTVaVio2WhmZVJZbk5QsK7nGP5twhcFJaaTCwE6WTMcmjXWslM0yUyFQKDsm3YClelTbTQh5WiU2w_gm5xJhhZUIrYqsZJxVuebKBJDP1C-0L1hOfTOGwiXOGV0yI_kFyU_tNDvCyS8eAkjmM--aoh0vmPPV_eH5BHk_INJbnomr_pHoXvbOOpe9vrgJYHfBBB6_kGLoWMQsgK2ZTQi_IIwFHbQVCJ7jAFrzUfRkSs_I2o6mY5FT9Tv0kwA-NYb0-Ga6z4xILgDuzOHFQomT0wN6-vzaiS1Y-XHQFb2T_vctWHWdcBy_bhuWJvdTu4OAbKJ2naf9BSqWHuk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cell+cycle+in+sporadic+melanoma&rft.jtitle=International+journal+of+dermatology&rft.au=Czajkowski%2C+Rafa%C5%82&rft.au=Drewa%2C+Tomasz&rft.au=Wo%C5%BAniak%2C+Alina&rft.au=Krzyzy%C5%84ska-Malinowska%2C+Ewa&rft.date=2002-09-01&rft.issn=0011-9059&rft.volume=41&rft.issue=9&rft.spage=550&rft_id=info:doi/10.1046%2Fj.1365-4362.2002.01601.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0011-9059&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0011-9059&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0011-9059&client=summon |